These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37848996)

  • 21. Increased percentages of PD-1 on CD4+ T cells is associated with higher INF-γ production and altered IL-17 production in patients with systemic lupus erythematosus.
    Dolff S; Quandt D; Feldkamp T; Jun C; Mitchell A; Hua F; Specker C; Kribben A; Witzke O; Wilde B
    Scand J Rheumatol; 2014; 43(4):307-13. PubMed ID: 25088926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus.
    Yang JH; Zhang J; Cai Q; Zhao DB; Wang J; Guo PE; Liu L; Han XH; Shen Q
    Rheumatology (Oxford); 2005 Oct; 44(10):1245-54. PubMed ID: 15987711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1+CXCR5-CD4+T cells are correlated with the severity of systemic lupus erythematosus.
    Lin J; Yu Y; Ma J; Ren C; Chen W
    Rheumatology (Oxford); 2019 Dec; 58(12):2188-2192. PubMed ID: 31180450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response.
    Lee JM; Chen MH; Chou KY; Chao Y; Chen MH; Tsai CY
    Lupus Sci Med; 2022 Jun; 9(1):. PubMed ID: 35738802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
    Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
    Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.
    Wu D; Liu Y; Pang N; Sun M; Wang X; Haridia Y; Zhao F; Qin Y; Fan W; Guo X; Ding J
    Medicine (Baltimore); 2019 Oct; 98(43):e17608. PubMed ID: 31651870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis.
    Nie M; Liu Y; Li XX; Min YN; Yang DD; Li Q; Feng Q; Hou Y; Li GS; Sun JZ; Hou M; Shi Y
    Thromb Haemost; 2019 May; 119(5):758-765. PubMed ID: 30808044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD19
    Xiong H; Tang Z; Xu Y; Shi Z; Guo Z; Liu X; Tan G; Ai X; Guo Q
    Adv Rheumatol; 2022 Dec; 62(1):48. PubMed ID: 36494762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequencies of PD-1- and PD-L1- positive T CD3
    Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
    Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
    Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
    Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of circulating CXCR3
    Han L; Yang X; Yu Y; Wan W; Lv L; Zou H
    Mod Rheumatol; 2019 May; 29(3):461-469. PubMed ID: 29694256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
    Porichis F; Hart MG; Zupkosky J; Barblu L; Kwon DS; McMullen A; Brennan T; Ahmed R; Freeman GJ; Kavanagh DG; Kaufmann DE
    J Virol; 2014 Mar; 88(5):2508-18. PubMed ID: 24352453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus.
    Lee J; Shin EK; Lee SY; Her YM; Park MK; Kwok SK; Ju JH; Park KS; Kim HY; Cho ML; Park SH
    Immunology; 2014 Aug; 142(4):573-80. PubMed ID: 24495300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus.
    Méndez-Flores S; Hernández-Molina G; Azamar-Llamas D; Zúñiga J; Romero-Díaz J; Furuzawa-Carballeda J
    Cytokine; 2019 Jul; 119():95-112. PubMed ID: 30903869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus.
    Bijl M; Horst G; Limburg PC; Kallenberg CG
    Ann Rheum Dis; 2001 May; 60(5):523-6. PubMed ID: 11302879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-22 production of effector CD4
    Dolff S; Scharpenberg C; Specker C; Kribben A; Witzke O; Wilde B
    Eur J Med Res; 2019 Jul; 24(1):24. PubMed ID: 31331400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
    Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
    Front Immunol; 2022; 13():830606. PubMed ID: 35935985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of PD-1 and its ligands and expansion of T peripheral helper cells in the nephritic kidneys of lupus-prone BXSB-
    Moriyama R; Katsumata Y; Okamoto Y; Harigai M
    Lupus; 2024 Jul; 33(8):816-827. PubMed ID: 38622764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.
    Braun NA; Celada LJ; Herazo-Maya JD; Abraham S; Shaginurova G; Sevin CM; Grutters J; Culver DA; Dworski R; Sheller J; Massion PP; Polosukhin VV; Johnson JE; Kaminski N; Wilkes DS; Oswald-Richter KA; Drake WP
    Am J Respir Crit Care Med; 2014 Sep; 190(5):560-71. PubMed ID: 25073001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4⁺CD25⁺Foxp3⁺ Treg and CD3⁻CD19⁺ B cells.
    Dal Ben ER; do Prado CH; Baptista TS; Bauer ME; Staub HL
    Rev Bras Reumatol; 2014; 54(3):241-6. PubMed ID: 25054604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.